DAXOR CORP (DXR) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Daxor Corporation's Annual Meeting of Shareholders held on June 24, 2025. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, primarily marketing the FDA-cleared BVA-100® Blood Volume Analyzer.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial performance details.
Material Changes and Voting Results
The filing details the election of directors and the ratification of the independent auditor. All director nominees were elected with overwhelming support, and the auditor was ratified.
| Director Nominee | For Votes | Withheld Votes |
|---|---|---|
| Henry D. Cremisi, MD | 3,493,651 | 1,899 |
| Edward Feuer | 3,493,138 | 2,412 |
| Joy Goudie, Esq. | 3,493,551 | 1,999 |
| Michael Feldschuh | 3,478,230 | 17,320 |
| Jonathan Feldschuh | 3,473,576 | 21,974 |
| Caleb DesRosiers, Esq. | 3,493,551 | 1,999 |
Other Matters:
- Ratification of Auditor: Bush & Associates, CPA was ratified as the independent registered public accounting firm.
- Vote Breakdown: 3,494,574 For, 100 Against, 876 Abstain.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the impact of hiring sales staff and expanding distribution channels. Management notes that actual results may differ due to risks including:
- Post-market clinical data collection activities.
- Market and physician acceptance of products.
- Competitive product offerings and intellectual property protection.
- FDA regulatory actions.
- Integration of acquired businesses.
No specific financial guidance or numerical outlook was provided in this document.
Key Facts for Investor Verification
- Meeting Date: Confirm the Annual Meeting occurred on June 24, 2025.
- Board Composition: Verify the terms of the newly elected directors expire at the next annual meeting (noted as 2025 in the text, which may be a clerical error in the source given the current date).
- Auditor Status: Confirm Bush & Associates, CPA remains the independent auditor.
- Financial Data: Note that this 8-K contains no financial results; verify current financial health via recent 10-Q/10-K filings.